BioPharma Dive36m
BridgeBio oncology spinout to go public in blank-check merger
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...
manilatimes3h
American Kidney Fund Raises Awareness for Rare Kidney Diseases for Rare Disease Day
"Living with kidney disease is a difficult challenge to navigate for patients and their families, and it can feel even more isolating and frustrating when you are living with a rare kidney disease,” ...
Verve Therapeutics: Key Data Catalysts, Major Share Price Volatility In Play In Q2
Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.
Hosted on MSN3h
Alltrna plans to tackle rare diseases using tRNA-based therapies
Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...
Vertex Pharmaceuticals gets CHMP opinion recommending Kaftrio label expansion
Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
BioSpace20h
Vertex Severs Liver Gene Therapies Partnership with Verve
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...